Adrenergic and v1-ergic agonists/antagonists affecting recovery from brain trauma in the lund project act on astrocytes

Current Signal Transduction Therapy

Volumn 7, Issue 1, 2012, Pages 43-55

  Peng, Liang ^a   Du, Ting ^a   Xu, Junnan ^a   Song, Dan ^a   Li, Baoman ^a   Zhang, Meixia ^a   Hertz, Leif ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

2 adrenergic agonist; 1 adrenergic antagonist; AKT; Astrocytes; Brain edema; EGF receptor; ERK; NKCC1; Potassium; Vasopressin

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETAXOLOL; DEXMEDETOMIDINE; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN NKCC1; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; UNCLASSIFIED DRUG; VASOPRESSIN;

ASTROCYTE; AUTOCRINE EFFECT; BRAIN EDEMA; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; NEUROPROTECTION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRAUMATIC BRAIN INJURY;

EID: 84861926111     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436212799278115     Document Type: Review

References (143)

1. Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004; 129: 1021-9. (Pubitemid 39556253)
2. Marmarou A, Signoretti S, Aygok G, Fatouros P, Portella G. Traumatic brain edema in diffuse and focal injury: cellular or vasogenic? Acta Neurochir Suppl 2006; 96: 24-9.
3. Katayama Y, Becker DP, Tamura T, Hovda DA. Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J Neurosurg 1990; 73: 889-900.
4. Reinert M, Khaldi A, Zauner A, Doppenberg E, Choi S, Bullock R. High extracellular potassium and its correlates after severe head injury: relationship to high intracranial pressure. Neurosurg Focus 2000; 8: e10.
5. Hertz L. Bioenergetics of cerebral ischemia: a cellular perspective. Neuropharmacology 2008; 55: 289-309.
6. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99: 4-9. (Pubitemid 47072553)
7. Grände PO. New haemodynamic aspects on treatment of posttraumatic brain oedema. Swedish Society of Anaesthesia and Intensive Care 1992; 6: 41-6.
8. Asgeirsson B, Grände PO, Nordström C.H. A new therapy of posttrauma brain oedema based on haemodynamic principles for brain volume regulation. Intensive Care Med 1994; 20(4): 260-7. (Pubitemid 24132365)
9. Grände PO. The Lund Concept for the treatment of severe head trauma-physiological principles and clinical application. Intensive Care Med 2006; 32(10): 1475-84.
10. Grände PO. The Lund concept: a well-defined therapy within the prescribed norms. Intensive Care Med 2007; 33:559-60.
11. Rabinstein AA. Treatment of cerebral edema. Neurologist 2006; 12: 59-73.
12. De Raedt S, Haentjens P, De Smedt A, et al. Pre-stroke use of betablockers does not affect ischaemic stroke severity and outcome. Eur J Neurol 2011; [Epub ahead of print].
13. Maier C, Steinberg GK, Sun GH, Zhi GT, Maze M. Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia. Anesthesiology 1993; 79: 306-12. (Pubitemid 23224843)
14. Kuhmonen J, Pokorn J, Miettinen R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology 1997; 87: 371-7. (Pubitemid 27435380)
15. Jolkkonen J, Puurunen K, Koistinaho J, et al. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol 1999; 372: 31-6. (Pubitemid 29229861)
16. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care 2009; 13: R75.
17. Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol 2011; 28: 3-6.
18. Graffagnino C, Olson DM, James ML. A physiological study comparing sedation with dexmedetomidine compared to propofol in ventilated patients with brain injury. Neurocrit Care 2011; 15: s169.
19. Li B, Du T, Li H, et al. Signalling pathways for transactivation by dexmedetomidine of epidermal growth factor receptors in astrocytes and its paracrine effect on neurons. Br J Pharmacol 2008; 154: 191-203. (Pubitemid 351620397)
20. Bekar LK, He W, Nedergaard M. Locus coeruleus alphaadrenergic-mediated activation of cortical astrocytes in vivo. Cereb Cortex 2008; 18: 2789-95.
21. Hertz L, Chen Y, Gibbs ME, Zang P, Peng L. Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders? Curr Drug Targets CNS Neurol Disord 2004; 3: 239-67. (Pubitemid 38854918)
22. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem Int 2010; 57: 411-20.
23. Dorn GW 2nd, Oswald KJ, McCluskey TS, Kuhel DG, Liggett SB. Alpha2A-adrenergic receptor stimulated calcium release is transduced by Gi-associated G(beta gamma)-mediated activation of phospholipase C. Biochemistry 1997; 36: 6415-23. (Pubitemid 27231399)
24. Delaney AJ, Crane JW, Sah P. Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 2007; 56: 880-92. (Pubitemid 350181353)
25. Gibson SK, Gilman AG. Gialpha and Gbeta subunits both define selectivity of G protein activation by alpha2-adrenergic receptors. Proc Natl Acad Sci U S A 2006; 103: 212-7. (Pubitemid 43076129)
26. Engelhard K, Werner C, Kaspar S, et al. Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 2002; 96: 450-7. (Pubitemid 34121758)
27. Enkvist MO, Hämäläinen H, Jansson CC, et al. Coupling of astroglial alpha 2-adrenoreceptors to second messenger pathways. J Neurochem 1996; 66: 2394-401. (Pubitemid 26159074)
28. Huang R, Hertz L. Receptor subtype and dose dependence of dexmedetomidine-induced accumulation of [14C]glutamine in astrocytes suggests glial involvement in its hypnotic-sedative and anesthetic-sparing effects. Brain Res 2000; 873: 297-301. (Pubitemid 30619056)
29. Nahorski SR, Batta MI, Barnett DB. Measurement of betaadrenoceptor antagonists in biological fluids using a radioreceptor assay. Eur J Pharmacol 1978; 52: 393-6. (Pubitemid 9114159)
30. Sastre M, Guimón J, García-Sevilla JA. Relationships between beta-and alpha2-adrenoceptors and G coupling proteins in the human brain: effects of age and suicide. Brain Res 2001; 898: 242-55. (Pubitemid 32299953)
31. Aoki C, Pickel VM. Ultrastructural relations between betaadrenergic receptors and catecholaminergic neurons. Brain Res Bull 1992; 29: 257-63.
32. Summers RJ, Papaioannou M, Harris S, Evans BA. Expression of beta 3-adrenoceptor mRNA in rat brain. Br J Pharmacol 1995; 116: 2547-8.
33. Magistretti PJ. Regulation of glycogenolysis by neurotransmitters in the central nervous system. Diabete Metab 1988; 14: 237-46.
34. Subbarao KV, Hertz L. Effect of adrenergic agonists on glycogenolysis in primary cultures of astrocytes. Brain Res 1990; 536: 220-6.
35. Du T, Li B, Li H, Li M, Hertz L, Peng L. Signaling pathways of isoproterenol-induced ERK1/2 phosphorylation in primary cultures of astrocytes are concentration-dependent. J Neurochem 2010; 115: 1007-23.
36. Kimelberg HK, Narumi S, Bourke RS. Enzymatic and morphological properties of primary rat brain astrocyte cultures, and enzyme development in vivo. Brain Res 1978; 153: 55-77. (Pubitemid 9025355)
37. Meier E, Hertz L, Schousboe A. Neurotransmitters as developmental signals. Neurochem Int 1991; 19: 1-15.
38. Gharami K, Das S. Delayed but sustained induction of mitogenactivated protein kinase activity is associated with beta-adrenergic receptor-mediated morphological differentiation of astrocytes. J Neurochem 2004; 88: 12-22. (Pubitemid 38030204)
39. Pierce KL, Tohgo A, Ahn S, Field ME, Luttrell LM, Lefkowitz RJ. Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors. J Biol Chem 2001; 276: 23155-60.
40. Peng L. Transactivation in astrocytes as a novel mechanism of neuroprotection. In: Hertz L, Ed. Non-neuronal cells of the nervous system: function and dysfunction. Amsterdam, Elsevier: 2004; pp. 503-18.
41. Zwick E, Daub H, Aoki N, et al. Critical role of calciumdependent epidermal growth factor receptor transactivation in PC12 cell membrane depolarization and bradykinin signaling. J Biol Chem 1997; 272: 24767-70. (Pubitemid 27415645)
42. Piiper A, Elez R, You SJ, et al. Cholecystokinin stimulates extracellular signal regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase Cepsilon. J Biol Chem 2003; 278: 7065-72. (Pubitemid 36800703)
43. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001; 8: 11-31. (Pubitemid 32520251)
44. Sahin U, Weskamp G, Kelly K, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-79. (Pubitemid 38282960)
45. Keates S, Sougioultzis S, Keates AC, et al. cag+ Helicobacter pylori induce transactivation of the epidermal growth factor receptor in AGS gastric epithelial cells. J Biol Chem 2001; 276: 48127-34.
46. Piepkorn M, Lo C, Plowman G. Amphiregulin-dependent proliferation of cultured human keratinocytes: autocrine growth, the effects of exogenous recombinant cytokine, and apparent requirement for heparin-like glycosaminoglycans. J Cell Physiol 1994; 159: 114-20. (Pubitemid 24234583)
47. Du T, Yang X, Peng L. mRNA expression of EGF family in primary cultures of astrocytes. Zhong Guo Yi Ke Da Xue Xue Bao 2007; 36: 500-1.
48. Opanashuk LA, Mark RJ, Porter J, Damm D, Mattson MP, Seroogy KB. Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and antiexcitotoxic action. J Neurosci 1999; 19: 133-46. (Pubitemid 29028956)
49. Nakagawa T, Sasahara M, Hayase Y, et al. Neuronal and glial expression of heparin-binding EGF-like growth factor in central nervous system of prenatal and early-postnatal rat. Brain Res Dev Brain Res. 1998; 108: 263-72. (Pubitemid 28332837)
50. Hagihara H, Hara M, Tsunekawa K, Nakagawa Y, Sawada M, Nakano K. Tonic-clonic seizures induce division of neuronal progenitor cells with concomitant changes in expression of neurotrophic factors in the brain of pilocarpine-treated mice. Brain Res Mol Brain Res 2005; 139: 258-66. (Pubitemid 41317939)
51. Yamada M, Ikeuchi T, Hatanaka H. The neurotrophic action and signalling of epidermal growth factor. Prog Neurobiol 1997; 51: 19-37. (Pubitemid 27080813)
52. Peng L, Li B, Du T, et al. Astrocytic transactivation by alpha2Aadrenergic and 5-HT2B serotonergic signaling. Neurochem Int 2010; 57: 421-31.
53. Oksvold MP, Thien CB, Widerberg J, Chantry A, Huitfeldt HS, Langdon WY. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oncogene 2003; 22: 8509-18. (Pubitemid 37523902)
54. Grövdal LM, Stang E, Sorkin A, Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004; 300: 388-95. (Pubitemid 39314428)
55. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004; 23: 7957-68. (Pubitemid 39468854)
56. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992; 31: 7152-4.
57. Li B, Zhang S, Zhang H, et al. Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berl) 2008; 201: 443-58.
58. Du T, Song D, Li H, et al. Stimulation by vasopressin of ERK phosphorylation and vector-driven water flux in astrocytes is transactivation-dependent. Eur J Pharmacol 2008; 587: 73-7.
59. Virtanen R. Pharmacological profiles of medetomidine and its antagonist, atipamezole. Acta Vet Scand Suppl 1989; 85: 29-37.
60. Ihalainen JA, Tanila H. In vivo regulation of dopamine and noradrenaline release by alpha2A-adrenoceptors in the mouse nucleus accumbens. J Neurochem 2004; 91: 49-56. (Pubitemid 39314936)
61. Owesson CA, Seif I, McLaughlin DP, Stamford JA. Different alpha(2) adrenoceptor subtypes control noradrenaline release and cell firing in the locus coeruleus of wildtype and monoamine oxidase-A knockout mice. Eur J Neurosci 2003; 18: 34-42. (Pubitemid 36920843)
62. U'Prichard DC, Snyder SH. Distinct alpha-noradrenergic receptors differentiated by binding and physiological relationships. Life Sci 1979; 24: 79-88. (Pubitemid 9107790)
63. Heal DJ, Butler SA, Prow MR, Buckett WR. Quantification of presynaptic 2-adrenoceptors in rat brain after short-term DSP-4 lesioning. Eur J Pharmacol 1993; 249: 37-41.
64. Cai JX, Ma YY, Xu L, Hu XT. Reserpine impairs spatial working memory performance in monkeys: reversal by the alpha2-adrenergic agonist clonidine. Brain Res 1993; 614: 191-6. (Pubitemid 23181168)
65. Arnsten AF, Cai JX. Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 1993; 14: 597-603. (Pubitemid 23347893)
66. Segal IS, Vickery RG, Walton JK, Doze VA, Maze M. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha2 adrenergic receptor. Anesthesiology 1988; 69: 818-23. (Pubitemid 19021625)
67. Horvath G, Kovacs M, Szikszay M, Benedek G. Drugs acting at calcium channels can influence the hypnotic-anesthetic effect of dexmedetomidine. Acta Biochim Biophys 1991-1992; 26: 75-81.
68. Peng L, Yu ACH, Fung KY, Prevot V, Hertz L. a-Adrenergic stimulation of ERK phosphorylation in astrocytes is 2-specific and may be mediated by transactivation. Brain Res 2003; 978: 65-71. (Pubitemid 36776625)
69. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-8.
70. Du T, Li B, Liu S, et al. ERK phosphorylation in intact, adult brain by alpha(2)-adrenergic transactivation of EGF receptors. Neurochem Int 2009; 55: 593-600.
71. Sorkin A, Waters C, Overholser KA, Carpenter G. Multiple autophosphorylation site mutations of the epidermal growth factor receptor. Analysis of kinase activity and endocytosis. J Biol Chem 1991; 266: 8355-62. (Pubitemid 21906518)
72. Morandell S, Stasyk T, Skvortsov S, Ascher S, Huber LA. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 2008; 8: 4383-401.
73. Soler C, Beguinot L, Sorkin A, Carpenter G. Tyrosine phosphorylation of ras GTPase-activating protein does not require association with the epidermal growth factor receptor. J Biol Chem 1993; 268: 22010-9. (Pubitemid 23320709)
74. Wilson LK, Luttrell DK, Parsons JT, Parsons SJ. pp60c-src Tyrosine kinase, myristylation, and modulatory domains are required for enhanced mitogenic responsiveness to epidermal growth factor seen in cells overexpressing c-src. Mol Cell Biol 1989; 9: 1536-44. (Pubitemid 19095193)
75. Wu W, Graves LM, Gill GN, Parsons SJ, Samet JM. Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J Biol Chem 2002; 277: 24252-7. (Pubitemid 34951942)
76. Justicia C, Planas AM. Transforming growth factor-a acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1998; 19: 128-32.
77. Rajakumaraswamy N, Ma D, Hossain M, Sanders RD, Franks NP, Maze M. Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models. Neurosci Lett 2006; 409: 128-33. (Pubitemid 44634964)
78. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha2A-adrenoceptor subtype. Eur J Pharmacol 2004; 502: 87-97. (Pubitemid 39311368)
79. Scheinin H, Karhuvaara S, Olkkola KT, et al. Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol Ther 1992; 52: 537-46.
80. Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth 2008; 100: 697-700. (Pubitemid 351774374)
81. Zhao Z, Code WE, Hertz L. Dexmedetomidine, a potent and highly specific alpha2 agonist, evokes cytosolic calcium surge in astrocytes but not in neurons. Neuropharmacology 1992; 31: 1077-9.
82. Opanashuk LA, Hauser KF. Opposing actions of the EGF family and opioids: heparin binding-epidermal growth factor (HB-EGF) protects mouse cerebellar neuroblasts against the antiproliferative effect of morphine. Brain Res 1998; 804: 87-94. (Pubitemid 28410482)
83. Gunn-Moore FJ, Williams AG, Toms NJ, Tavaré JM. Activation of mitogen-activated protein kinase and p70S6 kinase is not correlated with cerebellar granule cell survival. Biochem J 1997; 324: 365-9. (Pubitemid 27267976)
84. Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D. Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2010; 54: 710-6.
85. Chen Y, Zhao Z, Code WE, Hertz L. A correlation between dexmedetomidine-induced biphasic increases in free cytosolic calcium concentration and energy metabolism in astrocytes. Anesth Analg 2000; 91: 353-7. (Pubitemid 30624296)
86. Dahmani S, Paris A, Jannier V, et al. Dexmedetomidine increases hippocampal phosphorylated extracellular signal-regulated protein kinase 1 and 2 content by an alpha 2-adrenoceptor-independent mechanism: evidence for the involvement of imidazoline I1 receptors. Anesthesiology 2008;108: 457-66. (Pubitemid 351304239)
87. Kempski O, von Rosen S, Weigt H, Staub F, Peters J, Baethmann A. Glial ion transport and volume control. Ann N Y Acad Sci 1991; 633: 306-17.
88. Yan Y, Dempsey RJ, Flemmer A, Forbush B, Sun D. Inhibition of Na(+)-K(+)-Cl(-) cotransporter during focal cerebral ischemia decreases edema and neuronal damage. Brain Res 2003; 961: 22-31. (Pubitemid 36084465)
89. Lu KT, Cheng NC, Wu CY, Yang YL. NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade. Crit Care Med 2008; 36: 917-22.
90. Cai L, Du T, Song D, Li B, Hertz L, Peng L. Astrocyte ERK phosphorylation precedes K(+)-induced swelling but follows hypotonicity-induced swelling. Neuropathology 2011; 31: 250-64.
91. Jayakumar AR, Panickar KS, Curtis KM, Tong XY, Moriyama M, Norenberg MD. Na-K-Cl cotransporter-1 in the mechanism of cell swelling in cultured astrocytes after fluid percussion injury. J Neurochem 2011; 117: 437-48.
92. Walz W, Hertz L. Acute and chronic effects of lithium in therapeutically relevant concentrations on potassium uptake into astrocytes. Psychopharmacology (Berl) 1982; 78: 309-13. (Pubitemid 13218564)
93. Walz W, Hertz L. Intense furosemide-sensitive potassium accumulation in astrocytes in the presence of pathologically high extracellular potassium levels. J Cereb Blood Flow Metab 1984; 4: 301-4. (Pubitemid 14080162)
94. Akiyama K, Miyashita T, Mori T, Mori N. Expression of the Na+-K+-2Cl-cotransporter in the rat endolymphatic sac. Biochem Biophys Res Commun 2007; 364: 913-7. (Pubitemid 350087888)
95. Kanaka C, Ohno K, Okabe A, et al. The differential expression patterns of messenger RNAs encoding K-Cl cotransporters (KCC1, 2) and Na-K-2Cl cotransporter (NKCC1) in the rat nervous system. Neuroscience 2001; 104: 933-46. (Pubitemid 32701957)
96. Mikawa S, Wang C, Shu F, Wang T, Fukuda A, Sato K. Developmental changes in KCC1, KCC2 and NKCC1 mRNAs in the rat cerebellum. Dev Brain Res 2002; 136: 93-100. (Pubitemid 34718115)
97. Somjen GG. Ion regulation in the brain: implications for pathophysiology. Neuroscientist 2002; 8: 254-67. (Pubitemid 34538793)
98. Walz W. Potassium homeostasis in the brain at the organ and cell level. In: Hertz L, Ed. Non-neuronal cells of the nervous system: function and dysfunction. Amsterdam: Elsevier. 2004; pp. 595-609. (Pubitemid 137640694)
99. Chen Y, McNeill JR, Hajek I, Hertz L. Effect of vasopressin on brain swelling at the cellular level: do astrocytes exhibit a furosemide-vasopressin- sensitive mechanism for volume regulation? Can J Physiol Pharmacol 1992; 70 Suppl: 367-73.
100. Heinemann U, Lux HD. Ceiling of stimulus induced rises in extracellular potassium concentration in the cerebral cortex of cat. Brain Res 1977; 120: 231-49. (Pubitemid 8012038)
101. Hansen AJ. Effect of anoxia on ion distribution in the brain. Physiol Rev 1985; 65: 101-48. (Pubitemid 15165386)
102. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011; 17: 439-47.
103. Darman RB, Forbush B. A regulatory locus of phosphorylation in the N terminus of the Na-K-Cl cotransporter, NKCC1. J Biol Chem 2002; 277: 37542-50.
104. Pedersen SF, O'Donnell ME, Anderson SE, Cala PM. Physiology and pathophysiology of Na+/H+ exchange and Na+-K+-2Cl-cotransport in the heart,brain, and blood. Am J Physiol Regul Integr Comp Physiol 2006; 291: 1-25.
105. Su G, Haworth RA, Dempsey RJ, Sun D. Regulation of Na(+)-K(+)-Cl(-) cotransporter in primary astrocytes by dibutyryl cAMP and high [K(+)](o). Am J Physiol Cell Physiol 2000; 279: 1710-21.
106. Zhao Z, Hertz L, Code WE. Effects of benzodiazepines on potassium-induced increase in free cytosolic calcium concentration in astrocytes: interactions with nifedipine and the peripheral-type benzodiazepine antagonist PK 11195. Can J Physiol Pharmacol 1996; 74: 273-7. (Pubitemid 26227498)
107. Hurtado O, Cárdenas A, Lizasoain I, et al. Up-regulation of TNFalpha convertase (TACE/ADAM17) after oxygen-glucose deprivation in rat forebrain slices. Neuropharmacology 2001; 40: 1094-102. (Pubitemid 32530616)
108. Jian Liu K, Rosenberg GA. Matrix metalloproteinases and free radicals in cerebral ischemia. Free Radic Biol Med. 2005; 39: 71-80. (Pubitemid 40733117)
109. Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases.Curr Pharm Des 2009; 15: 2319-35.
110. Flemmer AW, Gimenez I, Dowd BF, Darman RB, Forbush B. Activation of the Na-K-Cl cotransporter NKCC1 detected with a phospho-specific antibody. J Biol Chem 2002; 277: 37551-8.
111. Kurihara K, Nakanishi N, Moore-Hoon ML, Turner RJ. Phosphorylation of the salivary Na(+)-K(+)-2Cl(-) cotransporter. Am J Physiol Cell Physiol 2002; 282: 817-23.
112. Jayakumar AR, Liu M, Moriyama M, et al. Na-K-Cl cotransporter-1 in the mechanism of ammonia-induced astrocyte swelling. J Biol Chem 2008; 283: 33874-82.
113. Jayakumar AR, Valdes V, Norenberg MD. The Na-K-Cl cotransporter in the brain edema of acute liver failure. J Hepatol 2011; 54: 272-8.
114. Xue Z, Li B, Gu L, et al. Increased Na, K-ATPase alpha2 isoform gene expression by ammonia in astrocytes and in brain in vivo. Neurochem Int 2010; 57: 395-403.
115. Kala G, Kumarathasan R, Peng L, Leenen FH, Hertz L. Stimulation of Na+,K+-ATPase activity, increase in potassium uptake, and enhanced production of ouabain-like compounds in ammoniatreated mouse astrocytes. Neurochem Int 2000; 36: 203-11. (Pubitemid 30047012)
116. Hannemann A, Flatman PW. Phosphorylation and transport in the Na-K-2Cl cotransporters, NKCC1 and NKCC2A, compared in HEK-293 cells. PLoS One 2011; 6: e17992.
117. Goyagi T, Kimura T, Nishikawa T, Tobe Y, Masaki Y. Betaadrenoreceptor antagonists attenuate brain injury after transient focal ischemia in rats. Anesth Analg 2006; 103: 658-63. (Pubitemid 44542920)
118. Goyagi T, Horiguchi T, Nishikawa T, Tobe Y. Post-treatment with selective 1 adrenoceptor antagonists provides neuroprotection against transient focal ischemia in rats. Brain Res 2010; 1343: 213-7.
119. Goyagi T, Nishikawa T, Tobe Y. Neuroprotective effects and suppression of ischemia-induced glutamate elevation by 1-adrenoreceptor antagonists administered before transient focal ischemia in rats. J Neurosurg Anesthesiol 2011; 23: 131-7.
120. Iwata M, Inoue S, Kawaguchi M, Nakamura M, Konishi N, Furuya H. Posttreatment but not pretreatment with selective betaadrenoreceptor 1 antagonists provides neuroprotection in the hippocampus in rats subjected to transient forebrain ischemia. Anesth Analg 2010; 110: 1126-32.
121. Thenuwara K, Todd MM, Brian JE Jr. Effect of mannitol and furosemide on plasma osmolality and brain water. Anesthesiology 2002; 96: 416-21. (Pubitemid 34121753)
122. Artru AA, Powers KM. Furosemide decreases cerebrospinal fluid formation during desflurane anesthesia in rabbits. J Neurosurg Anesthesiol 1997; 9: 166-74. (Pubitemid 27157388)
123. Clasen RA, Pandolfi S, Casey D Jr. Furosemide and pentobarbital in cryogenic cerebral injury and edema. Neurology 1974; 24: 642-8.
124. Gaab M, Knoblich OE, Schupp J, Herrmann F, Fuhrmeister U, Pflughaupt KW. Effect of furosemide (lasix) on acute severe experimental cerebral edema. J Neurol 1979; 220: 185-97. (Pubitemid 9135361)
125. Tornheim PA, McLaurin RL, Sawaya R. Effect of furosemide on experimental traumatic cerebral edema. Neurosurgery 1979; 4: 48-52. (Pubitemid 9118634)
126. Wilkinson HA, Rosenfeld S.R. Furosemide and mannitol in the treatment of acute experimental intracranial hypertension. Neurosurgery 1983; 12: 405-10. (Pubitemid 13130052)
127. Albright AL, Latchaw RE, Robinson AG. Intracranial and systemic effects of osmotic and oncotic therapy in experimental cerebral edema. J Neurosurg 1984; 60: 481-9. (Pubitemid 14194091)
128. Roberts PA, Pollay M, Engles C, Pendleton B, Reynolds E, Stevens FA. Effect on intracranial pressure of furosemide combined with varying doses and administration rates of mannitol. J Neurosurg 1987; 66: 440-6. (Pubitemid 17031474)
129. Todd MM, Cutkomp J, Brian JE. Influence of mannitol and furosemide, alone and in combination, on brain water content after fluid percussion injury. Anesthesiology 2006; 105: 1176-81. (Pubitemid 44808581)
130. Wu PH, Phillis JW. Receptor-mediated noradrenaline stimulation of (Na+-K+) ATPase in rat brain cortical homogenates. Gen Pharmacol 1979; 10: 189-92. (Pubitemid 9199804)
131. Wu PH, Phillis JW. Characterization of receptor-mediated catecholamine activation of rat brain cortical Na+-K+-ATPase. Int J Biochem 1980; 12: 353-9. (Pubitemid 11194762)
132. Hajek I, Subbarao KV, Hertz L. Acute and chronic effects of potassium and noradrenaline on Na+, K+-ATPase activity in cultured mouse neurons and astrocytes. Neurochem Int 1996; 28: 335-42. (Pubitemid 26063023)
133. Trabold R, Krieg S, Schöller K, Plesnila N. Role of vasopressin V(1a) and V2 receptors for the development of secondary brain damage after traumatic brain injury in mice. J Neurotrauma 2008; 25: 1459-65.
134. Niermann H, Amiry-Moghaddam M, Holthoff K, Witte OW, Ottersen OP. A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex. J Neurosci 2001; 21: 3045-51. (Pubitemid 32323486)
135. Del Bigio MR, Fedoroff S. Swelling of astroglia in vitro and the effect of arginine vasopressin and atrial natriuretic peptide. Acta Neurochir Suppl (Wien) 1990; 51: 14-6.
136. Sarfaraz D, Fraser CL. Effects of arginine vasopressin on cell volume regulation in brain astrocyte in culture. Am J Physiol 1999; 276: 596-601.
137. Gagnon KB, Delpire E. Multiple pathways for protein phosphatase 1 (PP1) regulation of Na-K-2Cl cotransporter (NKCC1) function: the N-terminal tail of the Na-K-2Cl cotransporter serves as a regulatory scaffold for Ste20-related proline/alanine-rich kinase (SPAK) and PP1. J Biol Chem 2010; 285: 14115-21.
138. Østby I, Øyehaug L, Einevoll GT, et al. Astrocytic mechanisms explaining neural-activity-induced shrinkage of extraneuronal space. PLoS Comput Biol 2009; 5: e1000272.
139. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997; 17: 171-80. (Pubitemid 27008860)
140. Zelenina M. Regulation of brain aquaporins. Neurochem Int 2010; 57: 468-88.
141. Hamann S, Herrera-Perez JJ, Zeuthen T, Alvarez-Leefmans FJ. Cotransport of water by the Na+-K+-2Cl(-) cotransporter NKCC1 in mammalian epithelial cells. J Physiol 2010; 588: 4089-101.
142. Zeuthen T. Water-transporting proteins. J Membr Biol 2010; 234: 57-73.
143. Arima H, Yamamoto N, Sobue K, et al. Hyperosmolar mannitol simulates expression of aquaporins 4 and 9 through a p38 mitogenactivated protein kinase-dependent pathway in rat astrocytes. J Biol Chem 2003; 278: 44525-34. (Pubitemid 37377205)